Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape
PLOS Pathogens · 18.05.2026 · 22 (5) · e1014223
DOI: 10.1371/journal.ppat.1014223 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 18.05.2026. Verfasst von Fan Bu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America. Hauptthemen laut MEDLINE: Single-Domain Antibodies, SARS-CoV-2, Spike Glycoprotein, Coronavirus, Antibodies, Viral. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
SARS-CoV-2 continues to accumulate spike mutations that erode the efficacy of antibody therapeutics. The Q493E mutation in the spike RBD, present in recent Omicron subvariants, enables escape from many antibodies and nanobodies, including our Nanosota-9A nanobody, which neutralizes Omicron JN.1 (Q493) but not KP.3 (E493). To address this, we applied a structure-guided in vitro evolution strategy to engineer Nanosota-9A, generating Nanosota-9B, which binds the KP.3 RBD with high affinity but shows reduced binding to JN.1 RBD. To regain breadth, we engineered a bispecific nanobody combining Nanosota-9A and -9B, which effectively neutralizes both JN.1 and KP.3 in infection assays. Our results provide proof of concept for an “update and reuse” strategy: applying structure-guided engineering to update and reuse validated nanobodies to overcome variant escape. This strategy offers a practical path to maintain therapeutic coverage as the virus evolves, supporting more efficient use of research resources and faster responses to emerging variants.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, Minnesota, United States of America.
- Center for Emerging Viruses, University of Minnesota, Minneapolis, Minnesota, United States of America.
- Center for Predictive Medicine, University of Louisville, Kentucky, United States of America.
- Department of Microbiology and Immunology, University of Iowa, Iowa City, Iowa, United States of America.
- Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America.
- Department of Microbiology and Immunology, University of Louisville, Kentucky, United States of America.
ORCID-Profile: Fang Li
Förderung
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Bu, F., Saxena, D., Turner-Hubbard, H., Delaney, A., Batra, L., Fricke, C., Moye, S., Verma, A., Perlman, S., Bhandari, J., Liu, B., Ye, G., Zheng, J., & Li, F. (2026). Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape. PLOS Pathogens, 22(5), e1014223. https://doi.org/10.1371/journal.ppat.1014223
Vancouver
Bu F, Saxena D, Turner-Hubbard H, Delaney A, Batra L, Fricke C, et al. Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape. PLOS Pathogens. 2026;22(5):e1014223. doi:10.1371/journal.ppat.1014223
BibTeX
@article{Bu2026,
author = {Bu, Fan and Saxena, Divyasha and Turner-Hubbard, Hailey and Delaney, Amy and Batra, Lalit and Fricke, Charlie and Moye, Skyler and Verma, Abhishek and Perlman, Stanley and Bhandari, Janarjan and Liu, Bin and Ye, Gang and Zheng, Jian and Li, Fang},
title = {Update and reuse: Structure-guided nanobody evolution against SARS-CoV-2 escape},
journal = {PLOS Pathogens},
year = {2026},
volume = {22},
number = {5},
pages = {e1014223},
doi = {10.1371/journal.ppat.1014223}
}
EUVIMED